Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review.

ERJ Open Res

Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Published: October 2022

Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy. NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the , involve primarily the lungs, on average 1 year after the start of treatment, and are not associated with immunosuppressive treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703143PMC
http://dx.doi.org/10.1183/23120541.00364-2022DOI Listing

Publication Analysis

Top Keywords

ntm infections
12
immune checkpoint
8
checkpoint inhibitors
8
systematic review
8
occurring icis
8
icis therapy
8
nontuberculous mycobacterial
4
infections
4
mycobacterial infections
4
infections cancer
4

Similar Publications

Clinically significant hemoptysis and all-cause mortality in patients with nontuberculous mycobacterial pulmonary disease.

Respir Med

January 2025

Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Department of Microbiology, Harvard Medical School, Boston, United States. Electronic address:

Background: Hemoptysis is one of the major symptoms in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). However, its prevalence, incidence, and impact on long-term prognosis remain uncertain. We evaluated the incidence of clinically significant hemoptysis, and determined its association with mortality in patients with NTM-PD.

View Article and Find Full Text PDF

Unlabelled: The complex (MAC) is a common causative agent causing nontuberculous mycobacterial (NTM) pulmonary disease worldwide. Whole-genome sequencing was performed on a total of 203 retrospective MAC isolates from respiratory specimens. Phylogenomic analysis identified eight subspecies and species.

View Article and Find Full Text PDF

Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium abscessus (M. abscessus) are important pathogens that can cause lung diseases.

View Article and Find Full Text PDF

Objective: The global prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) has been steadily increasing. A few small retrospective studies have reported a poor prognosis associated with chronic pulmonary aspergillosis (CPA) as a complication of NTM-PD. Furthermore, the prognostic impact of CPA may have been inadequately assessed due to differences in background factors.

View Article and Find Full Text PDF

Host Long Noncoding RNAs as Key Players in Mycobacteria-Host Interactions.

Microorganisms

December 2024

Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK 74078, USA.

Mycobacterial infections, caused by various species within the Mycobacterium genus, remain one of the main challenges to global health across the world. Understanding the complex interplay between the host and mycobacterial pathogens is essential for developing effective diagnostic and therapeutic strategies. Host long noncoding RNAs (lncRNAs) have emerged as key regulators in cellular response to bacterial infections within host cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!